Current State of Biomarkers in Bipolar Disorder

Scola, Gustavo; Andreazza, Ana Cristina

doi:10.1007/s11920-014-0514-4

Cited by 22 publications

(22 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes in mitochondrial function and redox modulation patterns were strongly associated with lipid peroxidation and DNA aberrations, which include changes in methylated and oxidized DNA. 3 Changes in protein conformation due to carbonylation and nitrosylation were also found; however, these alterations do not represent a strong correlation with the pathophysiology of BD. 127 Importantly, our group and others are already investigating studies with regard to how the lipid peroxidation process and DNA aberrations caused by mitochondrial dysfunction occur in BD.…”

Section: Peripheral Alterationsmentioning

confidence: 99%

“…These alterations could be directly correlated to dysregulation of the molecular pathways of inflammation and neurotrophins. 3,4 The factors that regulate neurological cells are expressed in a region-specific manner in the brain and the peripheral tissues. This suggests the possibility of using peripheral markers to address alterations in the brain that occur during the development of BD and other psychiatric disorders.…”

Section: Introductionmentioning

confidence: 99%

“…Biomarkers are essential tools necessary to provide insights into the molecular alterations in BD. 2,3 Due to the heterogeneity of this disorder, the possibility of developing specific biomarker is still being explored; however, a set of biomarkers might be available to identify subgroups of patients and also develop new treatments. Our goal is to incorporate and critically review the published literature with regard to the morphological, genetic, and molecular alterations found in BD.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Biomarkers for bipolar disorder: current insights

Duong¹,

Syed²,

Scola³

2015

CBF

Self Cite

View full text Add to dashboard Cite

Abstract:Currently, there exists a lack of definitive diagnostic tools for neuropsychiatric disorders, particularly molecular markers that could help assess the illness and develop more personalized treatments for different disorders. Understanding of the neurobiology and potential novel treatments for bipolar disorder (BD), one of the most complex psychiatric illnesses, remains poor. This review aims to compile the most reproducible findings regarding the molecular, genetic, and structural changes that occur in BD. Neuroimaging studies have indicated alterations in neural circuits, disrupted white matter integrity, alterations in reward activation, and decreased gray matter (GM) volume. Genetic studies have identified variations in a number of genes that confer risk for BD development. Studies involving peripheral biomarkers include alterations in the levels of oxidative stress, inflammation, and neurotrophins. These potential molecular markers could be used as tools for diagnosis, to assess illness progression, and to help with the improvement of more specific and personalized treatments for patients with BD. Identification of biologically relevant markers could improve the quality of life of patients with BD and revolutionize public health.

show abstract

Section: Peripheral Alterationsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for bipolar disorder: current insights

Duong¹,

Syed²,

Scola³

2015

CBF

Self Cite

View full text Add to dashboard Cite

show abstract

“…The abnormalities pertaining to activity in IFG could be a biomarker. Future studies might explore whether this failure to activate IFG is specific to BD and whether it is predictive of treatment response72630. The relatively high cost and limited availability of expertise in fMRI remain a limiting factor.…”

Section: Potential Biomarkers In Bipolar Disorder: a Critical Appraisalmentioning

confidence: 99%

“…In the subsequent years, there has been a rise in the number of studies looking at the peripheral biomarkers in BD730. The potential advantages of this approach are its easy accessibility through venepuncture, low-cost and potential for wider availability and amenability to large-scale studies.…”

Section: Peripheral Biomarkersmentioning

confidence: 99%

Potential biomarkers for bipolar disorder: Where do we stand?

Sagar¹,

Pattanayak²

2017

Indian J Med Res

View full text Add to dashboard Cite

Bipolar disorder (BD) is a severe, recurrent mood disorder, associated with a significant morbidity and mortality, with high rates of suicides and medical comorbidities. There is a high risk of mood disorders among the first-degree relatives of patients with BD. In the current clinical practice, the diagnosis of BD is made by history taking, interview and behavioural observations, thereby lacking an objective, biological validation. This approach may result in underdiagnosis, misdiagnosis and eventually poorer outcomes. Due to the heterogeneity of BD, the possibility of developing a single, specific biomarker is still remote; however, there is a set of promising biomarkers which may serve as predictive, prognostic or treatment markers in the future. The review presents a critical appraisal and update on some of the most promising candidates for biomarkers, namely, neuroimaging markers, peripheral biomarkers and genetic markers, including a brief discussion on cognitive endophenotypes as indicative of genetic risk. The lessons learnt from other fields and specialties in medicine need to be applied to psychiatry to translate the knowledge from ‘bench to bedside’ by means of clinically useful biomarkers. Overall, the biomarkers may help in pushing the shift towards personalized medicine for psychiatric patients.

show abstract

Relationship between serum vitamin D levels and inflammatory markers in acute stroke patients

et al. 2018

View full text Add to dashboard Cite

IntroductionLow serum vitamin D levels are associated with the development of poststroke depression (PSD). Inflammatory markers play an important role in pathophysiology of PSD. The relationship between vitamin D levels and inflammatory markers has been discussed in nonstroke individuals. The purposes of this study were to explore the relationship between vitamin D levels and inflammatory markers in acute stroke patients and examine the effect of vitamin D and inflammatory markers on PSD.MethodsA total of 152 acute stroke patients were recruited. Serum levels of 25‐hydroxyvitamin D and inflammatory markers were measured by standardized laboratory methods. Depression symptoms were assessed with the 17‐item Hamilton Depression Scale (HAMD‐17). Patients with the HAMD‐17 scores ≥7 were identified to have depression symptoms.ResultsSerum vitamin D levels were negatively correlated with serum levels of interleukin‐6 and high‐sensitivity C‐reactive protein (hsCRP) (r = −.244, p = .002; r = −.231, p = .004). Multiple regression analysis showed that interleukin‐6 and hsCRP levels were associated with vitamin D levels (B = −0.355, p = .003; B = −2.085, p = .006), whereas age, height, weight, leukocyte count, neutrophil ratio, and lymphocyte rate could be omitted without changing the results. In multivariate analyses, the serum levels of vitamin D and interleukin‐6 were associated with the development of PSD after adjusted possible variables (OR = 0.976, 95% CI: 0.958–0.994, p = .009; OR = 1.029, 95% CI: 1.003–1.055, p = .027).ConclusionsSerum vitamin D levels are inversely associated with the levels of interleukin‐6 and hsCRP, suggesting a potential anti‐inflammatory role for vitamin D in stroke individuals.

show abstract

Current State of Biomarkers in Bipolar Disorder

Cited by 22 publications

References 80 publications

Biomarkers for bipolar disorder: current insights

Biomarkers for bipolar disorder: current insights

Potential biomarkers for bipolar disorder: Where do we stand?

Relationship between serum vitamin D levels and inflammatory markers in acute stroke patients

Contact Info

Product

Resources

About